Rituximab biosimilar (Hisun Pharma/Beijing Mabworks Biotech)

利妥昔单抗生物类似药 (Hisun Pharma/Beijing Mabworks Biotech)

Report date: 2022/01/14 13:23:58

Base Information

Drug NameRituximab biosimilar (Hisun Pharma/Beijing Mabworks Biotech)
Drug Alias NameRecombinant chimeric anti-CD20 antibody (Hisun Pharma/Beijing Mabworks Biotech)重组人-鼠嵌合抗CD20单抗（海正药业/北京天广实生物）利妥昔单抗生物仿制药 (Hisun Pharma/Beijing Mabworks Biotech)
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Chimeric monoclonal antibodyBiologics > Biosimilar
Mechanisms of ActionAntibody-dependent cell-mediated cytotoxicity (ADCC) effectsComplement dependent cytotoxicity (CDC) effectsCD20-directed cytolytic effects +[4] 
TargetsB-lymphocyte antigen CD20
Therapy Area/IndicationsLymphoma, Large B-Cell, DiffuseLymphoma, Non-Hodgkin
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesZhejiang Hisun Pharmaceutical Co LtdBeijing Mabworks Biotech Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesZhejiang Hisun Pharmaceutical Co LtdBeijing Mabworks Biotech Co Ltd
Inactive CompaniesN/A
Active IndicationsLymphoma, Large B-Cell, Diffuse
Inactive IndicationsLymphoma, Non-Hodgkin

Other Information

ATC CodeL01XC02
Related LinksN/A